These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21109929)

  • 1. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
    Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
    Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
    Toyoda A; Kawana H; Azuhata K; Yu J; Omata A; Kishi H; Higashi M; Harigaya K
    Int J Oncol; 2009 Jan; 34(1):53-60. PubMed ID: 19082477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
    Tanaka N; Yoshida H; Suzuki Y; Harigaya K
    Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
    Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
    Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100P expression in ductal type of carcinoma ex pleomorphic adenoma.
    Hashimoto K; Yamamoto H; Shiratsuchi H; Nakashima T; Tamiya S; Higaki Y; Komune S; Tsuneyoshi M; Oda Y
    Am J Surg Pathol; 2011 Mar; 35(3):346-55. PubMed ID: 21317706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis.
    Kataoka A; Sadanaga N; Mimori K; Ueo H; Barnard GF; Sugimachi K; Auclair D; Chen LB; Mori M
    Clin Cancer Res; 2001 Sep; 7(9):2815-20. PubMed ID: 11555598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
    Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
    Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
    Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
    Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
    Serra KP; Sarian LO; Rodrigues-Peres RM; Vassallo J; Soares FA; Pinto GA; da Cunha IW; Shinzato JY; Derchain SF
    Acta Histochem; 2012 May; 114(3):226-31. PubMed ID: 21683430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
    Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.